8-K ·Filed Jun 2, 2026
8-K context-dependent: Items 5.02, 8.01
Actionable Insight • Neutral
Monitor for any future partnership or clinical milestones; the board addition and COO promotion suggest a focus on operational execution and strategic transactions, but the filing itself contains no near-term catalyst.
Final — all horizons settled through T+60d ⚠ clustered
ONCY ▼ -8.00% at T+60d
NEUTRAL call ✗ call lost -8.00% · α vs SPY -9.12% · entry $0.9300 → $0.8556
T+1d
-5.38%
call -5.38% · α -4.68%
$0.8800
settled 4mo ago
T+5d
-12.90%
call -12.90% · α -9.94%
$0.8100
settled 4mo ago
T+20d
-3.15%
call -3.15% · α -1.59%
$0.9007
settled 3mo ago
T+60d
-8.00%
call -8.00% · α -9.12%
$0.8556
settled 5w ago
Price Chart
Loading chart...
Executive Summary
Oncolytics Biotech announced the appointment of Stephen Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer. This is a routine organizational change with no material financial impact.
Key Facts
- Stephen Glover appointed as independent director, granted option to purchase 96,000 shares vesting over 3 years.
- John McAdory promoted to COO, previously EVP of Strategy and Operations; no additional compensation.
- Glover brings public company board and M&A experience, including chairing Ambrx during its $2B acquisition by J&J.
Financial Impact
No financial figures disclosed; director option grant is standard compensation.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (8 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000039 |
| Document: oncybodandcoo.htm | 0001129928-26-000039 |
| Document: 0001129928-26-000039-index-headers.html | 0001129928-26-000039 |
| Document: 0001129928-26-000039-index.html | 0001129928-26-000039 |
| Document: 0001129928-26-000039.txt | 0001129928-26-000039 |
15 reports for ONCY
67% Hit rate best @ T+5▲ +10.53%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $0.7720 $0.7700 | ▼ −0.26% | ▲ +0.24% | $0.6310 (−18.26%) |
Jul 20, 2026 10w ago | 8-K | $0.8500 $0.8122 | ▼ −4.45% | ▼ −4.02% | $0.6310 (−25.76%) |
Jul 13, 2026 11w ago | 8-K | $0.9289 $0.8533 | ▼ −8.14% | ▼ −7.35% | $0.6310 (−32.07%) |
Jun 16, 2026 15w ago | 8-K | $0.9495 $0.9409 | ▼ −0.91% | ▲ +1.33% | $0.6310 (−33.54%) |
Jun 2, 2026 17w ago | 8-K | $0.9300 $0.8100 | ▼ −12.90% | ▼ −9.94% | $0.6310 (−32.15%) |
Jun 1, 2026 17w ago | 8-K | $1.06 $0.8400 | ▼ −20.75% | ▼ −18.00% | $0.6310 (−40.47%) |
May 22, 2026 19w ago | 8-K | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
May 22, 2026 19w ago | Press Release | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
Apr 27, 2026 22w ago | 8-K | $0.9700 $0.9300 | ▼ −4.12% | ▼ −4.52% | $0.6310 (−34.95%) |
Apr 6, 2026 25w ago | 424B5 | $0.9000 $1.02 | ▼ −13.33% | ▼ −8.00% | $0.6310 (+29.89%) |
Showing 10 of 15
US Market Status
Market Closed — Opens Mon (38h 33m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access